Sign in

    Charles Anthony Butler • Rodman & Renshaw

    Anthony Butler is a Senior Equity Analyst at Rodman & Renshaw, specializing in healthcare sector research with an extensive focus on biotechnology and pharmaceutical companies. Over his career, he has covered 83 stocks, including major names such as AbbVie, Agilent, Zoetis, Abbott Laboratories, and Idenix Pharma, and achieved notable returns, with his buy call on Forty Seven Inc. (FTSV) generating a +651.8% return. Butler ranks with a 31.63% success rate and has delivered average returns across numerous ratings, demonstrating significant industry acumen. He began his Wall Street analyst career prior to 2009 and has built a reputation for in-depth sector analysis, holding FINRA credentials and securities licenses as required for research analysts at investment banks.

    Charles Anthony Butler's questions to Bioatla Inc (BCAB) leadership

    Charles Anthony Butler's questions to Bioatla Inc (BCAB) leadership • Q4 2024

    Question

    Charles Anthony Butler of Rodman & Renshaw asked if the HPV-positive head and neck cancer patients who responded were smokers and questioned the strategy of targeting mid-tier companies for partnerships.

    Answer

    Executive Eric Sievers addressed the partnering strategy, explaining that after a large company sought a multi-billion dollar opportunity, they recognized the value in engaging mid-tier firms for what they see as a $1B+ opportunity. Executive Jay Short noted he did not have the smoking correlation data for the HPV-positive cohort on hand but would obtain it.

    Ask Fintool Equity Research AI

    Charles Anthony Butler's questions to Bioatla Inc (BCAB) leadership • Q3 2024

    Question

    Charles Anthony Butler of Rodman & Renshaw asked for clarification on the CTLA-4 dosing strategy, questioning if patients might be up-titrated from 350 mg to 700 mg. He also inquired about the total number of patients anticipated for the ROR2 pivotal trial.

    Answer

    Executive Eric Sievers clarified that the ROR2 pivotal trial in head and neck cancer is anticipated to enroll approximately 570 patients to support full approval. Regarding CTLA-4 dosing, Sievers highlighted several instances of successful intra-patient dose escalation leading to reattainment of disease control, confirming that a planned dose escalation strategy for patients with insufficient clinical benefit is under active discussion.

    Ask Fintool Equity Research AI